FDA Grants Fast Track to AV-1959R for Alzheimer Prevention

The FDA granted Fast Track designation to AV-1959R, an investigational amyloid-beta (Aβ) vaccine from Nuravax, for the prevention of Alzheimer disease in cognitively unimpaired people with biomarker evidence of amyloid pathology, according to a company announcement. The designation covers a population with amyloid buildup in the brain and no symptoms, for whom no preventive therapy is approved.¹

AV-1959R is not approved for any use, and its safety and efficacy have not been established.¹ Nuravax is a spin-out of the Institute for Molecular Medicine (IMM), a nonprofit biomedical research organization in Huntington Beach, California, which developed the vaccine platform and supplied the drug product.¹

“Our goal is to stop amyloid buildup in people who are at risk but have no symptoms,” said Michael G. Agadjanyan, PhD, president of Nuravax and head of molecular immunology at IMM, in a statement. Lon S. Schneider, MD, professor at the Keck School of Medicine of USC and a medical consultant to Nuravax, said in a statement, “Fast Track enables more frequent interaction with the FDA.”¹

AV-1959R Fast Track designation and phase 2 AREVIA plans

Fast Track is intended to speed the development and review of therapies for serious conditions with unmet need. According to the company, the designation allows more frequent FDA interaction and may make AV-1959R eligible for rolling review, Accelerated Approval, and Priority Review if criteria are met.¹ Nuravax noted Fast Track does not guarantee faster development, review, or approval.

The company said the request was supported by published preclinical results and phase 1 data showing safety and strong immunogenicity.¹ Nuravax plans the phase 2 AREVIA study (NCT07827768) in 160 cognitively unimpaired adults with biomarker-confirmed amyloid pathology. Participants would receive 2 priming immunizations of AV-1959R followed by a booster at week 44, under IND 30925.

Endpoints include safety, with MRI monitoring for amyloid-related imaging abnormalities (ARIA), along with immunogenicity and changes in amyloid and tau biomarkers in blood and brain.¹ AV-1959R is built on the MultiTEP platform, which combines self-antigen B-cell epitopes with foreign T-helper epitopes to generate antibodies against pathological proteins. The company said the platform has also been applied to tau and alpha-synuclein.

AV-1959R phase 1 immunogenicity and safety data

The phase 1 trial (NCT06831812) was randomized, double-blind, and placebo-controlled, enrolling 16 cognitively unimpaired participants.² Twelve received AV-1959R at 100 µg or 300 µg and 4 received placebo, with 2 priming doses given 1 month apart.² The study assessed safety and immunogenicity, not clinical efficacy, and results were published in Molecular Neurodegeneration.²

READ MORE: Amyloid Vaccine AV-1959R Generates Antibodies in All Phase 1 Recipients

All 12 vaccine recipients developed anti-Aβ antibodies.² Geometric mean titers reached about 60,240 in the 100 µg cohort and 69,530 in the 300 µg cohort, while none of the 4 placebo recipients had a measurable response.²

In exploratory analyses, antibodies bound more strongly to aggregated Aβ species, including protofibrils and fibrils, than to oligomers, with little binding to monomeric Aβ.² Serum from vaccinated participants also bound amyloid plaques in cortical tissue from people with Alzheimer disease but not in non-Alzheimer control tissue.² Modeling projected titers remaining about 5-fold above baseline for roughly 1 year after priming, and investigators noted durability and clinical relevance still need prospective confirmation.^2,3

The company said the trial met its safety objectives, though the announcement did not report adverse event counts by arm.³ Schneider, a coauthor of the phase 1 publication, said the designation supports early dialogue with the agency on phase 3 design.^1,3

References

1. Nuravax receives FDA Fast Track designation for AV-1959R, an investigational vaccine designed to help prevent Alzheimer’s disease before symptoms begin. News release. Nuravax, Inc. Published October 20, 2026. Accessed October 21, 2026. https://www.prnewswire.com/news-releases/nuravax-receives-fda-fast-track-designation-for-av1959r-an-investigational-vaccine-designed-to-help-prevent-alzheimers-disease-before-symptoms-begin-302911695.html

2. Hovakimyan A, Madoyan H, Najarzadeh Z, et al. A randomized, placebo-controlled, double blind phase 1 trial of the Aβ vaccine, AV-1959R. Mol Neurodegener. Published online 2026. doi:10.1186/s13024-026-00980-y

3. Amyloid vaccine AV-1959R generates antibodies in all phase 1 recipients. NeurologyLive. Published October 20, 2026. Accessed October 21, 2026. https://www.neurologylive.com/view/amyloid-vaccine-av-1959r-generates-antibodies-phase-1-recipients